High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson’s disease (original) (raw)

References

1. Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590. https://doi.org/10.1002/mds.25945
   Article Google Scholar
2. Hornykiewicz O (2006) The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70:9–15
   Article CAS Google Scholar
3. Yang Y, Han CY, Guo L, Guan QB (2018) High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson’s disease and the relationship of pathological staging. Brain Behav 8(4):e00948. https://doi.org/10.1002/brb3.948
   Article PubMed PubMed Central Google Scholar
4. Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R (2015) Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci 125(10):717–725. https://doi.org/10.3109/00207454.2014.982795
   Article CAS PubMed Google Scholar
5. Chao Y, Wong SC, Tan EK (2014) Evidence of inflammatory system involvement in Parkinson’s disease. Biomed Res Int 2014:308654. https://doi.org/10.1155/2014/308654
   Article CAS PubMed PubMed Central Google Scholar
6. Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE (2009) Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 37(4):1107–1114. https://doi.org/10.1093/nar/gkn1011
   Article CAS PubMed PubMed Central Google Scholar
7. Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H (2009) Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Investig 89(8):948–959. https://doi.org/10.1038/labinvest.2009.47
   Article CAS PubMed Google Scholar
8. Thomas JO, Travers AA (2001) HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem Sci 26(3):167–174
   Article CAS Google Scholar
9. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME (2001) New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20(16):4337–4340. https://doi.org/10.1093/emboj/20.16.4337
   Article CAS PubMed PubMed Central Google Scholar
10. Todorova J, Pasheva E (2012) High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 3(1):214–218. https://doi.org/10.3892/ol.2011.459
    Article CAS PubMed Google Scholar
11. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Phys Cell Physiol 284(4):C870–C879. https://doi.org/10.1152/ajpcell.00322.2002
    Article CAS Google Scholar
12. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8(5):487–496. https://doi.org/10.1038/ni1457
    Article CAS PubMed Google Scholar
13. Fang P, Schachner M, Shen YQ (2012) HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 45(3):499–506. https://doi.org/10.1007/s12035-012-8264-y
    Article CAS PubMed Google Scholar
14. Lindersson EK, Hojrup P, Gai WP, Locker D, Martin D, Jensen PH (2004) alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 15(18):2735–2739
    CAS PubMed Google Scholar
15. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31(3):1081–1092. https://doi.org/10.1523/JNEUROSCI.3732-10.2011
    Article CAS PubMed PubMed Central Google Scholar
16. Rizzi L, Marques FC, Rosset I, Moriguchi EH, Picon PD, Chaves ML, Roriz-Cruz M (2014) C-reactive protein and cognition are unrelated to leukoaraiosis. ScientificWorldJournal 2014:121679–121678. https://doi.org/10.1155/2014/121679
    Article CAS PubMed PubMed Central Google Scholar
17. Song IU, Kim YD, Cho HJ, Chung SW (2013) Is neuroinflammation involved in the development of dementia in patients with Parkinson’s disease? Intern Med 52(16):1787–1792
    Article Google Scholar
18. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4(6):371–380. https://doi.org/10.1016/S1474-4422(05)70099-5
    Article CAS PubMed Google Scholar
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
    Article CAS Google Scholar
20. Song IU, Chung SW, Kim JS, Lee KS (2011) Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. Neurol Sci 32(1):31–34. https://doi.org/10.1007/s10072-010-0335-0
    Article PubMed Google Scholar
21. Santoro M, Maetzler W, Stathakos P, Martin HL, Hobert MA, Rattay TW, Gasser T, Forrester JV, Berg D, Tracey KJ, Riedel G, Teismann P (2016) In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson’s disease which can be attenuated by glycyrrhizin. Neurobiol Dis 91:59–68. https://doi.org/10.1016/j.nbd.2016.02.018
    Article CAS PubMed PubMed Central Google Scholar
22. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442
    Article CAS Google Scholar
23. Lee J, Taneja V, Vassallo R (2012) Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 91(2):142–149. https://doi.org/10.1177/0022034511421200
    Article CAS PubMed PubMed Central Google Scholar
24. Sasaki T, Liu K, Agari T, Yasuhara T, Morimoto J, Okazaki M, Takeuchi H, Toyoshima A, Sasada S, Shinko A, Kondo A, Kameda M, Miyazaki I, Asanuma M, Borlongan CV, Nishibori M, Date I (2016) Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson’s disease. Exp Neurol 275(Pt 1):220–231. https://doi.org/10.1016/j.expneurol.2015.11.003
    Article CAS PubMed Google Scholar
25. Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Iwata M, Tancharoen S, Oyama Y, Takenouchi K, Nawa Y, Arimura N, Jie MX, Shrestha B, Miura N, Shimizu T, Mera K, Arimura S, Taniguchi N, Iwasaka H, Takao S, Hashiguchi T, Maruyama I (2008) C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 17(3):129–138. https://doi.org/10.1016/j.carpath.2007.08.006
    Article CAS PubMed Google Scholar
26. Nawaz MI, Mohammad G (2015) Role of high-mobility group box-1 protein in disruption of vascular barriers and regulation of leukocyte-endothelial interactions. J Recept Signal Transduct Res 35(4):340–345. https://doi.org/10.3109/10799893.2014.984309
    Article CAS PubMed Google Scholar
27. Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D, Aluclu MU (2015) The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol Sci 36(3):423–428. https://doi.org/10.1007/s10072-014-1976-1
    Article PubMed Google Scholar

Download references